India and Germany partner on immunoglobulin technology transfer for organ transplant drugs
The Embassy of India in Berlin facilitated a technology transfer agreement between Neovii Biotech and VINS Bioproducts during the Indo-German Health Leadership Dialogue.
India and Germany forge key biopharmaceutical partnership
India's growing stature as a global healthcare and manufacturing hub has received another boost with a new bilateral biotechnology partnership. Indian pharmaceutical firm VINS Bioproducts Ltd and German firm Neovii Biotech GmbH have agreed to collaborate on the manufacturing, commercialisation, and direct technology transfer of critical immunoglobulin products to India.
The diplomatic breakthrough was facilitated by the Embassy of India in Berlin on the sidelines of the Indo-German Health Leadership Dialogue held on 13 October 2026. The two companies formally exchanged a Non-Disclosure Agreement (NDA) to set the collaboration in motion, as announced by the Indian mission.
What products are covered under the agreement?
The deal focuses on high-value biological products designed to handle complex medical procedures and rare disorders.
| Product Type | Primary Application | Key Benefit to India |
|---|---|---|
| Anti-thymocyte globulin | Human organ transplantation | Reduces risk of organ rejection |
| Specialised immunoglobulins | Treatment of rare blood disorders | Enables local manufacturing and supply |
Anti-thymocyte globulin plays an essential role in immunosuppressive therapy, helping prevent graft rejection in patients undergoing organ transplants while assisting in the treatment of specific blood disorders.
Boosting domestic manufacturing and healthcare self-reliance
By bringing cutting-edge biopharmaceutical technology into Indian facilities, the partnership significantly strengthens the country's domestic production capabilities for complex biological drugs.
The Indian Embassy noted that the collaboration will facilitate local manufacturing, technology transfer, and streamlined commercial distribution across Indian markets. In addition to securing affordable and timely access for patients, localising production aligns with India's broader push to build robust healthcare infrastructure and reduce dependence on foreign imports for life-saving biological therapies.
The agreement underscores the active role of Indian diplomatic channels in fostering strategic industrial ties and bringing advanced medical technology directly to domestic manufacturers.
Key numbers
| What | Figure | Source |
|---|---|---|
| Date of agreement exchange | 13 October 2026 | Embassy of India in Berlin |
| Date of official announcement | 16 October 2026 | Embassy of India in Berlin |
In this story
| Name | Role in the story |
|---|---|
| Neovii Biotech GmbH | German biotechnology firm transferring technology to India. |
| India | Recipient country of the biotech technology transfer and manufacturing. |
| Embassy of India, Berlin | Facilitated the agreement during the Indo-German Health Leadership Dialogue. |
| Germany | Partner country in the biotechnology agreement. |
| VINS Bioproducts Ltd | Indian company entering the partnership for immunoglobulin technology transfer. |
